Published • loading... • Updated
Novartis Says MS Pill Succeeds in Two Large Studies
Novartis said remibrutinib also slowed disability progression and plans to seek global approval after the late-stage studies.
- On Tuesday, Swiss drugmaker Novartis announced its oral drug remibrutinib outperformed Aubagio in reducing relapse rates for patients with relapsing multiple sclerosis, bolstering blockbuster prospects.
- The late-stage REMODEL-1 and REMODEL-2 trials compared remibrutinib against Aubagio, sold by Sanofi, testing the Bruton's tyrosine kinase inhibitor class in roughly 2,000 adults.
- UBS analyst Matt Weston wrote, "Overall, remi looks like it is at least a best-in-class oral agent," citing the drug's improved liver safety profile versus earlier BTK inhibitors.
- Investors are focused on remibrutinib, pelacarsen, and del-desiran, which together are seen generating more than $10 billion in peak annual sales, with remibrutinib alone potentially reaching $9 billion.
- Novartis plans to seek global regulatory approval for remibrutinib and will present full trial data at the MSToronto2026 medical conference, advancing the drug toward market.
Insights by Ground AI
20 Articles
20 Articles
Swiss pharmaceutical company Novartis announced that Lapsido (active ingredient: remibrutinib), an oral multiple sclerosis treatment under development, has achieved its primary endpoint in Phase 3 clinical trials. The company stated that it confirmed an effect of reducing relapses compared to existing treatments, and that no signs of liver toxicity—a concern during the development of drugs in the same class—were observed. Following this news, No…
Coverage Details
Total News Sources20
Leaning Left0Leaning Right5Center7Last UpdatedBias Distribution58% Center
Bias Distribution
- 58% of the sources are Center
58% Center
C 58%
R 42%
Factuality
To view factuality data please Upgrade to Premium
